Key result
Transcatheter aortic valve implantation with the CoreValve system in nonagenarians with severe aortic stenosis resulted in a 30-day all-cause mortality of 27.3% and significant hemodynamic improvement.
Why the study?
Does transcatheter aortic valve implantation (TAVI) improve clinical and echocardiographic outcomes in nonagenarians with severe aortic stenosis and high surgical risk?
Population
11 nonagenarians with severe aortic valve stenosis and elevated comorbidity index, mean age 92.6 ± 1.3…
Design
Case_series
Follow-up
6 months
Authors
Loading...
High early mortality warrants cautious selection for TAVI in nonagenarians; leaves open need for prospective validation in larger cohorts.
Observational (n=11)
No
Does transcatheter aortic valve implantation (TAVI) improve clinical and echocardiographic outcomes in nonagenarians with severe aortic stenosis and high surgical risk?
TAVI with the CoreValve system is feasible and provides significant symptomatic and hemodynamic improvements in nonagenarians with severe aortic stenosis, though it carries considerable periprocedural mortality and morbidity.
Akın et al. (2012) conducted an observational in Severe aortic valve stenosis (n=11). Transcatheter aortic valve implantation (CoreValve) was evaluated on 30-day all-cause mortality. Transcatheter aortic valve implantation with the CoreValve system in nonagenarians with severe aortic stenosis resulted in a 30-day all-cause mortality of 27.3% and significant hemodynamic improvement.